Adam Cotton
Principal Novartis Venture Fund
Adam Cotton, PhD, MBA, is an Principal at the Novartis Venture Fund in Cambridge, MA, where he invests in early-stage biotech companies across indications and modalities. He is a scientific co-founder of Epi Biologics and has helped guide the growth of Rezo Therapeutics and HYKU Biosciences from academic labs to emerging biotech companies. Prior to his venture work, he conducted antibody engineering research in the labs of Jim Wells and Ian Seiple. Dr. Cotton holds a PhD in Chemistry & Chemical Biology from UCSF, an MBA from the University of New Mexico, and a BA in Chemistry from Harvard University. He serves on multiple boards, including Arvada Therapeutics and Mediar Therapeutics.
Seminars
Defining Value, Differentiation & De-Risking in a Competitive Landscape
As the IPF field advances beyond proof-of-concept and into an era of increasing mechanistic diversity, the question is no longer whether IPF drug development is viable, but what makes an asset truly investable.
With new mechanisms emerging and the bar for differentiation rising, clarity on what constitutes a compelling therapeutic story has never been more critical. This panel brings together investors, strategic pharma, and M&A leaders to define what “good” looks like, and what it doesn’t, in today’s IPF landscape.
Key Discussion Points:
- What Builds Conviction Early? What efficacy signals, durability data, mechanistic rationale, safety profile, and translational evidence are required at preclinical and early clinical stages to generate real investor confidence?
- Differentiation vs. Incrementalism? In a field moving beyond simply slowing FVC decline, what level of clinical impact, biomarker validation, or combination rationale is needed to stand out from the noise?
- De-Risking, Timing & Strategic Positioning? How do investors evaluate first-in-class versus best-in-class strategies? What role do trial design, regulatory strategy, management credibility, and partnership readiness play in investment and acquisition decisions?
